Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Central Drugs Standard Control Organisation (CDSCO) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention RET gene, all published on June 26, 2026.
Last mentioned: Jun 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Central Drugs Standard Control Organisation (CDSCO) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention RET gene, all published on June 26, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RET gene. Shared-story counts are live from our verified record — not editorial picks.
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
RET gene is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
